PL2269622T3 - Sposób do modulowania wrażliwości na steroidy - Google Patents

Sposób do modulowania wrażliwości na steroidy

Info

Publication number: PL2269622T3
Authority: PL; Poland
Prior art keywords: steroid; enhancing; oligonucleotides used; cpg oligonucleotides; dependent patient
Prior art date: 2005-07-01

Application number

PL10162989T

Other languages

English (en)

Inventor

Robert Löfberg

Stein Oliver Von

Arezou Zargari

Original Assignee

Index Pharmaceuticals Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-01

Filing date

2006-06-29

Publication date

2014-05-30

2006-06-29 Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab

2014-05-30 Publication of PL2269622T3 publication Critical patent/PL2269622T3/pl

Links

150000003431 steroids Chemical class 0.000 title abstract 4
108091034117 Oligonucleotide Proteins 0.000 title abstract 3
230000001419 dependent effect Effects 0.000 title abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000000694 effects Effects 0.000 title 1
230000002708 enhancing effect Effects 0.000 title 1
239000003814 drug Substances 0.000 abstract 1
230000004968 inflammatory condition Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)

PL10162989T 2005-07-01 2006-06-29 Sposób do modulowania wrażliwości na steroidy PL2269622T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US69617305P	2005-07-01	2005-07-01
EP10162989.7A EP2269622B1 (en)	2005-07-01	2006-06-29	CpG oligonucleotides used for enhancing steroid activity in a steroid dependent patient
EP06748068A EP1901759B1 (en)	2005-07-01	2006-06-29	Immunostimulatory method

Publications (1)

Publication Number	Publication Date
PL2269622T3 true PL2269622T3 (pl)	2014-05-30

Family

ID=37604739

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL10162989T PL2269622T3 (pl)	2005-07-01	2006-06-29	Sposób do modulowania wrażliwości na steroidy
PL11166835T PL2380584T3 (pl)	2005-07-01	2006-06-29	Sposób do immunostymulacji

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL11166835T PL2380584T3 (pl)	2005-07-01	2006-06-29	Sposób do immunostymulacji

Country Status (14)

Country	Link
US (2)	US8258107B2 (pl)
EP (3)	EP1901759B1 (pl)
JP (3)	JP5074392B2 (pl)
AT (1)	ATE476193T1 (pl)
AU (1)	AU2006266503B2 (pl)
CA (1)	CA2612162C (pl)
CY (1)	CY1114965T1 (pl)
DE (1)	DE602006015963D1 (pl)
DK (2)	DK2380584T3 (pl)
ES (3)	ES2442090T3 (pl)
PL (2)	PL2269622T3 (pl)
PT (1)	PT2269622E (pl)
SI (2)	SI2380584T1 (pl)
WO (1)	WO2007004977A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2179737E (pt) *	2005-07-01	2013-12-05	Index Pharmaceuticals Ab	Método para modular a capacidade de resposta aos esteróides
SI2380584T1 (sl) *	2005-07-01	2014-04-30	Index Pharmaceuticals Ab	Imunostimulatorni postopek
AU2006306805A1 (en) *	2005-10-28	2007-05-03	Index Pharmaceuticals Ab	Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
CN101820908A (zh) *	2007-10-09	2010-09-01	科利制药公司	包含改性糖部分的免疫刺激寡核苷酸类似物
WO2009078793A1 (en)	2007-12-14	2009-06-25	Index Pharmaceuticals Ab	Method for predicting the response to a therapy
US20110182880A1 (en) *	2008-06-18	2011-07-28	Oliver Von Stein	Combination Therapies Against Cancer
ES2560782T3 (es)	2008-11-04	2016-02-22	Index Pharmaceuticals Ab	Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC
US9920317B2 (en)	2010-11-12	2018-03-20	The General Hospital Corporation	Polycomb-associated non-coding RNAs
EP3702460A1 (en)	2010-11-12	2020-09-02	The General Hospital Corporation	Polycomb-associated non-coding rnas
EP2596806A1 (en)	2011-11-25	2013-05-29	Index Pharmaceuticals AB	Method for prevention of colectomy
CN104583402A (zh)	2012-05-16	2015-04-29	Rana医疗有限公司	用于调节mecp2表达的组合物和方法
CN104583398A (zh)	2012-05-16	2015-04-29	Rana医疗有限公司	用于调节基因表达的组合物和方法
US10837014B2 (en)	2012-05-16	2020-11-17	Translate Bio Ma, Inc.	Compositions and methods for modulating SMN gene family expression
WO2016070060A1 (en)	2014-10-30	2016-05-06	The General Hospital Corporation	Methods for modulating atrx-dependent gene repression
US10900036B2 (en)	2015-03-17	2021-01-26	The General Hospital Corporation	RNA interactome of polycomb repressive complex 1 (PRC1)
US20180193270A1 (en)	2016-11-29	2018-07-12	PureTech Health LLC	Exosomes for delivery of therapeutic agents
GB201707503D0 (en) *	2017-05-10	2017-06-21	Index Pharmaceuticals Ab	New Therapy 3
GB201707501D0 (en) *	2017-05-10	2017-06-21	Index Pharmaceuticals Ab	New therapy 2
GB201707500D0 (en) *	2017-05-10	2017-06-21	Index Pharmaceuticals Ab	New therapy
GB201807312D0 (en) *	2018-05-03	2018-06-20	Index Pharmaceuticals Ab	Formulation
EP4147688A1 (en) *	2021-09-09	2023-03-15	InDex Pharmaceuticals AB	Enema formulation

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5149797A (en)	1990-02-15	1992-09-22	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
US5652355A (en)	1992-07-23	1997-07-29	Worcester Foundation For Experimental Biology	Hybrid oligonucleotide phosphorothioates
US6346614B1 (en)	1992-07-23	2002-02-12	Hybridon, Inc.	Hybrid oligonucleotide phosphorothioates
TW244371B (pl)	1992-07-23	1995-04-01	Tri Clover Inc
CA2105595A1 (en) *	1992-09-23	1994-03-24	Ramaswamy Narayanan	Antisense polynucleotides
US5849719A (en)	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
AU713040B2 (en)	1994-07-15	1999-11-18	University Of Iowa Research Foundation, The	Immunomodulatory oligonucleotides
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030078223A1 (en) *	1996-01-30	2003-04-24	Eyal Raz	Compositions and methods for modulating an immune response
CA2244946C (en)	1996-01-30	2010-04-13	The Regents Of The University Of California	Gene expression vectors which generate an antigen specific immune response and methods of using the same
SE9602300D0 (sv) *	1996-06-11	1996-06-11	Karolinska Innovations Ab	New composition and methods
WO1998016247A1 (en)	1996-10-11	1998-04-23	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2281838A1 (en) *	1997-02-28	1998-09-03	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en)	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) *	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (en)	1997-05-20	2007-08-22	Ottawa Health Research Institute	Processes for preparing nucleic acid constructs
US6589940B1 (en) *	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6133246A (en) *	1997-08-13	2000-10-17	Isis Pharmaceuticals Inc.	Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6218371B1 (en) *	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1077708A1 (en)	1998-05-06	2001-02-28	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
AU760795B2 (en)	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
JP2002521489A (ja)	1998-07-27	2002-07-16	ユニバーシティオブアイオワリサーチファウンデーション	ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
WO2001022972A2 (en) *	1999-09-25	2001-04-05	University Of Iowa Research Foundation	Immunostimulatory nucleic acids
IL148844A0 (en)	1999-09-27	2002-09-12	Coley Pharm Group Inc	Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
EP1688147A1 (en)	1999-09-27	2006-08-09	Coley Pharmaceutical Group, Inc.	Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon
US7223398B1 (en) *	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en) *	2000-03-03	2002-10-24	Bratzler Robert L.	Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US20020107212A1 (en)	2000-03-10	2002-08-08	Nest Gary Van	Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US6649341B1 (en) *	2000-04-19	2003-11-18	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Human glucocorticoid receptor 1A promoter and splice variants
EP1296714B1 (en) *	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US20020198165A1 (en) *	2000-08-01	2002-12-26	Bratzler Robert L.	Nucleic acids for the prevention and treatment of gastric ulcers
EP1366077B1 (en) *	2000-09-15	2011-05-25	Coley Pharmaceutical GmbH	PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
US6294382B1 (en) *	2000-11-27	2001-09-25	Isis Pharmaceuticals, Inc.	Antisense modulation of SRC-1 expression
AU2002248185A1 (en)	2000-12-14	2002-07-16	Coley Pharmaceutical Group, Inc.	Inhibition of angiogenesis by nucleic acids
JP2002257827A (ja) *	2001-03-01	2002-09-11	Jenokkusu Soyaku Kenkyusho:Kk	ステロイド応答性の検査方法
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
AU2002256359A1 (en)	2001-04-24	2002-11-05	Epigenesis Pharmaceuticals, Inc.	Antisense and anti-inflammatory based compositions to treat respiratory disorders
WO2003031573A2 (en) *	2001-10-05	2003-04-17	Coley Pharmaceutical Gmbh	Toll-like receptor 3 signaling agonists and antagonists
KR20050048539A (ko) *	2001-10-06	2005-05-24	메리얼엘엘씨	ＣｐＧ 제제 및 관련된 방법
AU2003203079B9 (en) *	2002-02-04	2009-01-15	Oncothyreon Inc.	Immunostimulatory, covalently lipidated oligonucleotides
NZ535952A (en) *	2002-04-04	2009-01-31	Coley Pharm Gmbh	Immunostimulatory G,U-containing oligoribonucleotides
US20060257851A1 (en) *	2002-11-26	2006-11-16	Itzhak Bentwich	Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7625872B2 (en)	2002-12-23	2009-12-01	Dynavax Technologies Corporation	Branched immunomodulatory compounds and methods of using the same
DK1992635T3 (da)	2002-12-23	2012-03-05	Dynavax Tech Corp	Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
JP4726630B2 (ja) *	2003-01-16	2011-07-20	イデラファーマシューティカルズインコーポレイテッド	修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節
CN101675993A (zh) *	2003-03-26	2010-03-24	赛托斯生物技术公司	Melan-a肽类似物-病毒样颗粒偶联物
EP1608403A2 (en) *	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
KR20060012622A (ko)	2003-05-16	2006-02-08	하이브리돈, 인코포레이티드	화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
US20050175630A1 (en) *	2003-12-23	2005-08-11	Eyal Raz	Immunogenic compositions and methods of use thereof
US20050158325A1 (en) *	2003-12-30	2005-07-21	3M Innovative Properties Company	Immunomodulatory combinations
JP2007523173A (ja)	2004-02-20	2007-08-16	イデラファーマシューティカルズインコーポレイテッド	修飾免疫調節オリゴヌクレオチドにより誘導された強力な粘膜免疫応答
SE0400399D0 (sv)	2004-02-20	2004-02-20	Index Pharmaceuticals Ab	Methods and compositions for the treatment or prevention of secondary ischemic injury
EP1716234B1 (de)	2004-02-20	2013-10-02	Mologen AG	Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren
BRPI0512110A (pt)	2004-06-15	2007-10-23	Idera Pharmaceutical Inc	multìmeros de oligonucleotìdeos imunoestimulatórios
WO2006015560A1 (de)	2004-08-09	2006-02-16	Mologen Ag	Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
PL1794174T3 (pl)	2004-09-01	2012-11-30	Dynavax Tech Corp	Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
EP1874325A2 (en)	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Methods for treating infectious disease exacerbated asthma
SI2380584T1 (sl) *	2005-07-01	2014-04-30	Index Pharmaceuticals Ab	Imunostimulatorni postopek
PT2179737E (pt) *	2005-07-01	2013-12-05	Index Pharmaceuticals Ab	Método para modular a capacidade de resposta aos esteróides

2006
- 2006-06-29 SI SI200631723T patent/SI2380584T1/sl unknown
- 2006-06-29 DK DK11166835.6T patent/DK2380584T3/da active
- 2006-06-29 DE DE602006015963T patent/DE602006015963D1/de not_active Expired - Lifetime
- 2006-06-29 PL PL10162989T patent/PL2269622T3/pl unknown
- 2006-06-29 EP EP06748068A patent/EP1901759B1/en not_active Expired - Lifetime
- 2006-06-29 ES ES11166835.6T patent/ES2442090T3/es not_active Expired - Lifetime
- 2006-06-29 EP EP10162989.7A patent/EP2269622B1/en not_active Expired - Lifetime
- 2006-06-29 JP JP2008519234A patent/JP5074392B2/ja not_active Expired - Fee Related
- 2006-06-29 ES ES06748068T patent/ES2349617T3/es not_active Expired - Lifetime
- 2006-06-29 AT AT06748068T patent/ATE476193T1/de not_active IP Right Cessation
- 2006-06-29 EP EP11166835.6A patent/EP2380584B1/en not_active Expired - Lifetime
- 2006-06-29 SI SI200631755T patent/SI2269622T1/sl unknown
- 2006-06-29 ES ES10162989.7T patent/ES2450593T3/es not_active Expired - Lifetime
- 2006-06-29 AU AU2006266503A patent/AU2006266503B2/en not_active Ceased
- 2006-06-29 WO PCT/SE2006/050229 patent/WO2007004977A1/en not_active Ceased
- 2006-06-29 CA CA2612162A patent/CA2612162C/en not_active Expired - Fee Related
- 2006-06-29 PL PL11166835T patent/PL2380584T3/pl unknown
- 2006-06-29 DK DK10162989.7T patent/DK2269622T3/en active
- 2006-06-29 US US11/917,482 patent/US8258107B2/en not_active Expired - Fee Related
- 2006-06-29 PT PT101629897T patent/PT2269622E/pt unknown
2012
- 2012-07-03 JP JP2012149378A patent/JP5945176B2/ja not_active Expired - Fee Related
- 2012-07-03 JP JP2012149379A patent/JP2012232989A/ja not_active Withdrawn
- 2012-07-09 US US13/544,353 patent/US8592390B2/en not_active Expired - Fee Related
2014
- 2014-03-07 CY CY20141100187T patent/CY1114965T1/el unknown

Also Published As

Publication number	Publication date
SI2380584T1 (sl)	2014-04-30
JP2012232988A (ja)	2012-11-29
US20120277293A1 (en)	2012-11-01
ATE476193T1 (de)	2010-08-15
JP5945176B2 (ja)	2016-07-05
ES2349617T3 (es)	2011-01-07
EP2269622B1 (en)	2013-12-25
SI2269622T1 (sl)	2014-05-30
WO2007004977A1 (en)	2007-01-11
US8258107B2 (en)	2012-09-04
CA2612162A1 (en)	2007-01-11
EP2380584A1 (en)	2011-10-26
DK2380584T3 (da)	2014-01-20
US8592390B2 (en)	2013-11-26
JP2012232989A (ja)	2012-11-29
PL2380584T3 (pl)	2014-03-31
EP2380584B1 (en)	2013-10-16
DE602006015963D1 (de)	2010-09-16
ES2442090T3 (es)	2014-02-10
AU2006266503B2 (en)	2011-12-08
CA2612162C (en)	2016-05-17
EP1901759B1 (en)	2010-08-04
AU2006266503A1 (en)	2007-01-11
EP1901759A1 (en)	2008-03-26
JP5074392B2 (ja)	2012-11-14
JP2008544983A (ja)	2008-12-11
US20100234449A1 (en)	2010-09-16
EP2269622A1 (en)	2011-01-05
PT2269622E (pt)	2014-03-20
DK2269622T3 (en)	2014-03-24
CY1114965T1 (el)	2016-12-14
ES2450593T3 (es)	2014-03-25

Publication	Publication Date	Title
CY1114965T1 (el)	2016-12-14	Cpg ολιγονουκλεοτιδια χρησιμοποιουμενα για ενισχυση της δραστικοτητας στεροειδων σε εναν εξαρτημενο απο στεροειδη ασθενη
ZA200702130B (en)	2008-09-25	Memantine for the treatment of childhood behavioral disorders
IL179828A0 (en)	2008-03-20	Therapeutic agents for the treatment of hmgb1-related pathologies
GB0522311D0 (en)	2005-12-07	Pharmaceutical compositions for the treatment of pain
TW200738242A (en)	2007-10-16	Dihydropteridinones in the treatment of respiratory diseases
PL381247A1 (pl)	2007-05-14	Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
SG161260A1 (en)	2010-05-27	Methods for treating infectious disease exacerbated asthma
MY145439A (en)	2012-02-15	Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
PL2083837T3 (pl)	2015-06-30	Terapeutyczne zastosowanie co najmniej jednej neurotoksyny botulinowej do leczenia bólu wywołanego co najmniej jednym środkiem przeciwnowotworowym
CY1112397T1 (el)	2015-12-09	Συνδυασμενη θεραπεια για την αντιμετωπιση του καρκινου
IL189104A (en)	2013-07-31	Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
TW200701977A (en)	2007-01-16	Novel use of peptide compounds for treating pain in painful diabetic neuropathy
PL2179737T3 (pl)	2014-01-31	Sposób do modulowania wrażliwości na steroidy
WO2008146172A3 (en)	2009-12-10	Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans
ITRM20050179A1 (it)	2006-10-14	Composizione impiegabile per il trattamento delle patologie paradontali.
BRPI0509667A (pt)	2007-10-09	azaquinazolinas substituìdas com eficácia antiviral
TW200640467A (en)	2006-12-01	Compounds and uses thereof
PL1874739T3 (pl)	2010-10-29	Farmaceutycznie czynne diazepany
PL1612210T3 (pl)	2008-02-29	Nowe analogi nitrobenzylotioinozyny
EP1827459A4 (en)	2010-01-13	THERAPEUTIC ANTISENSE OLIGONUCLEOTIDE COMPOSITION FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
IL186286A0 (en)	2008-01-20	Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
GB0305928D0 (en)	2003-04-23	Organic compounds
IL183926A0 (en)	2007-10-31	PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-kB ACTIVITY
ES1050463Y (es)	2002-08-01	Dispositivo terapeutico para el tratamiento de sintomas ocasionados por enfermedades.
RU2005128615A (ru)	2007-03-20	Средство для лечения заболеваний пародонта